Opzelura cream is contraindicated for specific populations, mainly involving pregnant women, patients at risk of infection, and individuals with special physiological conditions. The following points explain the prohibited population and their medical basis.

Opzelura cream is suitable for patients with specific skin diseases, mainly targeting mild to moderate atopic dermatitis and non segmental vitiligo. The following points explain the applicable population and their treatment basis.

Applicable Population

1. Patients with atopic dermatitis

(1) For patients aged 12 and above with mild to moderate atopic dermatitis, as a local treatment option.

(2) Suitable for those who have poor efficacy or intolerance to traditional topical corticosteroids.

2 Non segmental vitiligo patients

(1) Patients aged 12 and above with non segmental vitiligo on the face or body.

(2) Suitable for individuals with stable skin lesion area ≤ 10% of body surface area.

3 Specific Liver Function Patients

(1) Patients with mild to moderate liver function impairment do not need to adjust the dosage.

(2) Individuals with severe liver function impairment should use it with caution and closely monitor it.

4 patients with specific renal function

(1) Patients with mild to moderate renal impairment do not need to adjust the dosage.

(2) Patients with severe renal impairment need to evaluate the risk benefit ratio before use.

5 elderly patients

(1) Elderly patients aged 65 and above can use it safely.

(2) It should be noted that elderly patients may be more sensitive to medication.

special populations

Pregnant women

(1) Animal studies have shown that the drug may cause fetal malformations and is absolutely contraindicated during pregnancy.

(2) Women of childbearing age need to confirm their pregnancy status before taking medication, and efficient contraceptive measures should be taken during treatment.

2 active carriers

(1) Tuberculosis, hepatitis B and other chronic infection patients are prohibited, because JAK inhibitors may activate latent infection.

(2) When there is purulent skin infection (such as pyoderma), it is necessary to control the infection before considering medication.

Individuals with severe immune dysfunction

(1) When the CD4 count of HIV/AIDS patients is less than 200/μ L, it is contraindicated as it may worsen immune deficiency.

(2) Individuals receiving treatment with potent immunosuppressive agents (such as cyclosporine) should avoid combination therapy.

Individuals with allergies

(1) It is contraindicated for individuals who are allergic to Lucretinib or cream base ingredients such as propylene glycol.

(2) Individuals with a history of severe drug allergies need to undergo skin patch testing for evaluation.

5 Special physiological states

(1) Breastfeeding women should avoid using the medication as it may affect the baby's milk secretion.

(2) The safety of children under 12 years old has not been established and should be avoided.